jnj-77242113
janssen,protagonist therapeutics
['psoriasis', 'frontier 1', 'protagonist ']
icymi: read about the positive topline results from the phase 2b frontier 1 clinical trial evaluating the oral il-23r antagonist jnj-2113 in adult patients with moderate-to-severe plaque #psoriasis presented at #wcd2023.
Discovering and developing novel therapies through our proprietary technology platform. #biotech #lifesciences #innovation